Thanks for the info here Dew as this has potential implications for my largest holding, IMGN. The Tykerb+Femara combo attained a PFS of 8.2 months it appears in HER2-positive breast cancer patients. DNA will be testing T-DM1 (Herceptin plus IMGN's DM1 cell-killing agent) in a Phase III trial against Tykerb+Xeloda in second-line treatment of HER2 patients.
In a prior Phase I trial in the second-line setting, T-DM1 attained a PFS of 9.8 months. Do you know if the Tykerb+Femara trial was in a second-line setting? I just want to make sure I'm comparing apples to apples when I look at the 9.8 months PFS versus 8.2. I know the caveat is that these are two separate trials but I'm just curious if the patient type may at least be roughly similar in gauging the results.
Market Data 
Markets 
AI
